Full text is available at the source.
Abstract
The 2024 FLOW trial established semaglutide as the first GLP-1 receptor agonist to show a dedicated primary renal outcome benefit.
- SGLT2 inhibitors, semaglutide, and finerenone are compared based on their effectiveness and safety in treating type 2 diabetes with chronic kidney disease.
- A Bayesian network meta-analysis was conducted to evaluate these three therapies, all having contemporary phase 3 cardiorenal evidence.
- Patients with diabetic kidney disease continue to experience significant residual risks despite optimal treatment with renin-angiotensin system blockade.
Simplified